Citi has released a research report stating that Zhizhu (02513.HK) GLM-5.3 API is now open for calls, showcasing its leading performance in complex coding and long-cycle agency tasks. Despite a smaller parameter scale, the model achieved state-of-the-art performance in benchmark tests with open weights and scored 60 points in the Artificial Analysis Intelligence Index, matching Kimi 3 and surpassing Tongyi Qianwen 3.8 Max.
The bank estimates that the revenue share of the GLM model's OpenRouter has increased from 1% in January this year to 7% in July, leading DeepSeek's 6% and Moonscape's 3%. It believes that DeepSeek's recent price increase reflects healthy competition in the industry, while GLM 5.3 has regained its position on the Pareto frontier.
The recent weakness in stock prices may reflect an overreaction from the market to Anthropic's deceleration in annual recurring revenue. Citi maintains its 'Outperform' rating for Zhizhu with a target price of HKD 2061.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.








Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.






